WAYNE, Pa., Oct. 20, 2016
/PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"),
a fully integrated specialty pharmaceutical company focused on
developing, manufacturing and commercializing innovative treatments
for pain and other conditions, today announced that its third
quarter financial results will be released on Friday, November 4, 2016. Following the
announcement, Egalet's management will host a live conference call
and webcast at 8:30 a.m. Eastern Time
to review the company's financial and operating results and provide
a general business update.
Interested parties may listen to the call via a live audio
webcast which may be accessed by visiting Egalet's website. Please
connect to the website a few minutes prior to the live webcast to
ensure adequate time for any software download that may be needed
to access the webcast. Individuals also may participate in the call
by dialing 1-888-346-2615 (domestic) or 1-412-902-4253
(international) and asking for the "Egalet Earnings
Call." The replay will be available approximately two
hours after the call on the Egalet website.
About Egalet
Egalet, a fully integrated specialty
pharmaceutical company, is focused on developing, manufacturing and
commercializing innovative treatments for pain and other
conditions. Egalet has two approved products: OXAYDO®
(oxycodone HCI, USP) tablets for oral use only –CII and
SPRIX® (ketorolac tromethamine) Nasal Spray. In
addition, using its proprietary Guardian™ Technology, Egalet is
developing a pipeline of clinical-stage, product candidates that
are specifically designed to deter abuse by physical and chemical
manipulation. The lead programs, ARYMO™ ER, an
abuse-deterrent, extended-release, oral morphine formulation, and
Egalet-002, an abuse-deterrent, extended-release, oral oxycodone
formulation, are being developed for the management of pain severe
enough to require daily, around-the-clock, long-term opioid
treatment and for which alternative treatment options are
inadequate. Egalet's Guardian Technology can be applied broadly
across different classes of pharmaceutical products and can be used
to develop combination products that include multiple active
pharmaceutical ingredients with similar or different release
profiles. For additional information on Egalet, please visit
egalet.com. For full prescribing information on SPRIX, including
the boxed warning, please visit sprix.com. For full prescribing
information on OXAYDO, please visit oxaydo.com.
Investor and Media Contact:
E. Blair Clark-Schoeb
Senior Vice President, Communications
Email: bcs@egalet.com
Tel: 917-432-9275
Logo -
http://photos.prnewswire.com/prnh/20140219/NY67493LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/egalet-to-host-conference-call-and-webcast-to-discuss-third-quarter-2016-financial-results-on-november-4-2016-300347802.html
SOURCE Egalet Corporation